Clinical Trials Logo

Metastases clinical trials

View clinical trials related to Metastases.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06356779 Recruiting - Surgery Clinical Trials

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease

OLIGO-DK
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations. The primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.

NCT ID: NCT05195710 Recruiting - Metastases Clinical Trials

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Start date: November 16, 2022
Phase: Phase 1
Study type: Interventional

A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.

NCT ID: NCT04987086 Recruiting - Renal Cancer Clinical Trials

68Ga-PSMA PET in the Renal Cell Carcinoma

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma

NCT ID: NCT04967001 Recruiting - Prostatic Neoplasms Clinical Trials

68Ga-PSMA PET in the Prostate Cancer

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Efficacy of 68Ga PSMA PET / CT in the diagnosis of lymph node metastasis in patients with prostate cancer: a single center prospective randomized controlled trial. To identify and compare the diagnostic efficacy of 68Ga-PSMA PET/CT and mpMRI for lymph nodes in patients with newly diagnosed prostate cancer.

NCT ID: NCT04066322 Recruiting - Surgery Clinical Trials

Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

RMPanNET
Start date: August 25, 2019
Phase:
Study type: Observational [Patient Registry]

This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment. The willing of participants decide who receive surgery and who will continue to receive standard systemic treatment.

NCT ID: NCT02452294 Recruiting - Malignant Melanoma Clinical Trials

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

BUMPER
Start date: July 2015
Phase: Phase 2
Study type: Interventional

The study will enrol adult female and male patients with BRAF wild-type melanoma and brain metastases who are not eligible for surgery or radiosurgery and failed prior therapy with ipilimumab, and patients with BRAF V600 mutation-positive melanoma and brain metastases who are not eligible for surgery or radiosurgery and who failed prior therapy with a BRAF inhibitor.

NCT ID: NCT02036008 Recruiting - Cancer Clinical Trials

Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial

Start date: August 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if Gadofosveset Trisodium (Gdfos, Ablavar) is a useful magnetic resonance imaging (MRI) contrast agent in accurately diagnosing liver metastases compared to the standard agent gadobutrol (EcGd, Gadovist).